Scientific Abstracts
biological therapy is an effective mean in increasing functional capacity and joint mobility, decreasing disease activity, improving quality of life for AS patients. Currently available data do not adequately address what role physiotherapy may have on patients with AS receiving biological drugs [1] . There are a few studies evaluating the effects of exercises in patients with AS receiving TNFa inhibitors [2, 3] Methods: Patients were enrolled in a prospective study including 3 months of PT and 3 months of Y (with a specific focus on the control of breathingAi-jutsu). Each activity was performed bi-weekly in a dedicated facility. Patients were randomly allocated to either the group starting with PT or that starting with Y. After 3 months they switched to the other activity. At the beginning and at the end of each activity patients underwent a medical assessment of their physical status and were proposed questionnaires: 1) HAQ for disability in everyday life; 2) ZUNG self-rating depression scale; 3) Tampa scale for Kinesiophobia assessing the fear and avoidance of movement. Patients with FM compiled also the FIQ for the impact of FM in everyday life. All patients rated their physical pain by VAS (Visual Analogic Scale) from 0 to 10. Results: Thirteen patients with CA (77% female, median age 62 years, median disease duration 19 years) and 8 with FM (100% female, 56 years, 9 years) participated in the study. At baseline, there were no differences between CA and FM patients in terms of ZUNG, HAQ and Tampa scores. After 3 and 6 months of activity, all items had a tendency toward improvement, with a statistically significant reduction for VAS in both groups (nearly -30%). By intra-group comparison between the beginning and the end of each activity, we observed that patients with CA had a significant reduction of ZUNG and HAQ scores (50 vs 40.5 and 0.600 vs 0.475, respectively) during PT activity, while FM patients had a trend toward the increase of Tampa score (24.5 vs 34.5). During Y activity, significant reductions were observed in VAS score for CA patients (5 vs 2.5) and in Tampa Background: The therapy for axial spondyloarthritis (axSpA) is complex. Although anti-inflammatory medication is necessary for axSpA treament, the exercise therapy is required to maintain mobility. The limited data are available to evaluate the effect of exercise therapy on quality of life in axSpA, particularly in patients with the non-radiographic form of the disease (nr-axSpA). Objectives: To investigated the quality of life in axSpA subgroups, nr-axSpA and Ankylosing spondylitis (AS) in response to intensive rehabilitation programme Methods: 46 patients with axSpA characterised according to criteria of Assessment of SpondyloArthritis international Society (ASAS) as nr-axSpA (n=23) and AS (n=23) with stable disease and treatment underwent 24 weeks long intervention. The intervention consisted in twice a week outpatient group physiotherapy as exercise units of 60 minutes and a daily home-based exercise programme. All outcomes, disease activity (Bath AS Disease Activity Index, BASDAI and AS Disease Activity Index, ASDAS-CRP) and quality of life (AS quality of life, ASQoL and European quality of life, EurQoL) as well as patients self-reported outcomes such as "patients global assessment" and "pain assessment" were measured at baseline and at the end of exercise program. Results: Altogether, 41 axSpA patients (AS, n=22 and nr-axSpA, n=19) finished complete six months programme. The disease activity was improved in all axSpA patients (ASDAS-CRP 2.08±0.12 to 1.83±0.11, p<0.01), particularly in nr-axSpA subgroup, ASDAS-CRP (1.98±0.19 to 1.71±0.15, p<0.05). There were no differences in the changes in ASDAS-CRP and BASDAI over the exercise training between groups (data not shown). After exercise therapy, positive changes of "Patients global assessment", were evaluated by patients of both subgroups, nr-ax-SpA (33.42±5.13 to 23.68±4.11, p<0.01) and AS (35.22±3.94 to 25.2±2.92, p<0.01). The "assessment of pain during the last 7 days", however, was improved only by patients in the nr-axSpA subgroup (34.74±5.88 vs. 21.05±4.71, p<0.05). The quality of life, ASQoL was not changed after rehabilitation programme.
